[Federal Register Volume 87, Number 45 (Tuesday, March 8, 2022)]
[Notices]
[Page 12968]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-04829]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of an Exclusive Patent License: NCGC00413972 
and Its Related Analogs Consisting of an Imidazo-Pyrazine Scaffold Core 
for the Treatment or Prevention of Cancers Expressing the Mannose 
Receptor CD206, Including Both Solid Tumors and Hematological 
Malignancies

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Cancer Institute, an institute of the National 
Institutes of Health, Department of Health and Human Services, is 
contemplating the grant of an Exclusive Patent License to practice the 
inventions embodied in the Patent Applications listed in the 
Supplementary Information section of this notice to Macala Bio, Inc. 
located in 1000 NW Wall Street, Suite 220, Bend, OR 97703.

DATES: Only written comments and/or applications for a license which 
are received by the National Cancer Institute's Technology Transfer 
Center on or before March 23, 2022 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
and comments relating to the contemplated an Exclusive Patent License 
should be directed to: Eric Cheng, Ph.D., Licensing and Patenting 
Manager at (240)-276-5530 or [email protected].

SUPPLEMENTARY INFORMATION:

Intellectual Property

    United States Provisional Patent Application No. 62/950,488, filed 
19 December 2019 and entitled ``CD206 Modulators Their Use And Methods 
For Preparation'' [HHS Reference No. E-105-2019/0-US-01];
    PCT Patent Application PCT/US2020/065238, filed 16 December 2020 
and entitled ``CD206 Modulators Their Use And Methods For Preparation'' 
[HHS Reference No. E-105-2019-0-PCT-02].
    The patent rights in these inventions have been assigned and/or 
exclusively licensed to the government of the United States of America.
    The prospective exclusive license territory may be worldwide and 
the field of use may be limited to: NCGC00413972 and its related 
analogs consisting of an imidazo-pyrazine scaffold core for the 
treatment or prevention of cancers expressing the mannose receptor 
CD206, including both solid tumors and hematological malignancies.
    This technology discloses immunotherapy drugs, and to compounds 
that modulate CD206 as well as their use and methods for preparation.
    This notice is made in accordance with 35 U.S.C. 209 and 37 CFR 
part 404. The prospective exclusive license will be royalty bearing, 
and the prospective exclusive license may be granted unless within 
fifteen (15) days from the date of this published notice, the National 
Cancer Institute receives written evidence and argument that 
establishes that the grant of the license would not be consistent with 
the requirements of 35 U.S.C. 209 and 37 CFR part 404.
    In response to this Notice, the public may file comments or 
objections. Comments and objections, other than those in the form of a 
license application, will not be treated confidentially, and may be 
made publicly available.
    License applications submitted in response to this Notice will be 
presumed to contain business confidential information and any release 
of information in these license applications will be made only as 
required and upon a request under the Freedom of Information Act, 5 
U.S.C. 552.

    Dated: March 2, 2022.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer 
Institute.
[FR Doc. 2022-04829 Filed 3-7-22; 8:45 am]
BILLING CODE 4140-01-P